A Randomised, Double-Blind, Placebo-Controlled, 60 Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinsons Disease

This is a sub-trial of the following large MRFF Grant:
The Australian Parkinson’s Mission (APM) aims to identify therapies that will slow or stop disease progression in people with Parkinson’s disease (PD). APM is a collaborative of scientists, clinicians, pharma, and people with PD whose goal is to determine the causes of PD, identify effective therapeutics and fast track them to people with Parkinson’s. To accomplish this, the five year project will employ a unique model of inter-connected and mutually reinforcing clinical trials, genomics and biomarker development and phenotyping of patient derived stem cells. A series of multi-arm, multi-drug clinical trials involving hundreds of patients will be conducted at multiple sites across Australia to test repurposed and new drugs that have been prioritised for testing by an international panel of PD experts. Blood RNA and metabolite biomarkers will be identified for their ability to accurately diagnose patients and detect drug efficacy with greater
sensitivity than existing clinical measures.